Arnott ID - Search Results

1

Kalla R, Ventham NT, Satsangi J, Arnott ID. Kalla R, et al. Among authors: arnott id. BMJ. 2014 Nov 19;349:g6670. doi: 10.1136/bmj.g6670. BMJ. 2014. PMID: 25409896 Review. No abstract available.

2

Clinical use of Infliximab in Crohn's disease: the Edinburgh experience.

Arnott ID, McDonald D, Williams A, Ghosh S. Arnott ID, et al. Aliment Pharmacol Ther. 2001 Oct;15(10):1639-46. doi: 10.1046/j.1365-2036.2001.01092.x. Aliment Pharmacol Ther. 2001. PMID: 11564005 Free article. Clinical Trial.

3

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.

Arnott ID, Watts D, Satsangi J. Arnott ID, et al. Pharmacol Res. 2003 Jan;47(1):1-10. doi: 10.1016/s1043-6618(02)00264-5. Pharmacol Res. 2003. PMID: 12526855 Review.

4

Crohn's disease or Crohn's diseases?

Arnott ID, Satsangi J. Arnott ID, et al. Gut. 2003 Apr;52(4):460-1. doi: 10.1136/gut.52.4.460. Gut. 2003. PMID: 12631650 Free PMC article. No abstract available.

5

An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease.

Arnott ID, McNeill G, Satsangi J. Arnott ID, et al. Aliment Pharmacol Ther. 2003 Jun 15;17(12):1451-7. doi: 10.1046/j.1365-2036.2003.01574.x. Aliment Pharmacol Ther. 2003. PMID: 12823146 Free article.

6

Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn's disease are associated with disease severity but not NOD2/CARD15 mutations.

Walker LJ, Aldhous MC, Drummond HE, Smith BR, Nimmo ER, Arnott ID, Satsangi J. Walker LJ, et al. Among authors: arnott id. Clin Exp Immunol. 2004 Mar;135(3):490-6. doi: 10.1111/j.1365-2249.2003.02392.x. Clin Exp Immunol. 2004. PMID: 15008984 Free PMC article.

7

NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe?

Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, Morecroft J, Anderson N, Kelleher D, O'Sullivan M, McManus R, Satsangi J. Arnott ID, et al. Genes Immun. 2004 Aug;5(5):417-25. doi: 10.1038/sj.gene.6364111. Genes Immun. 2004. PMID: 15190267

8

Disease location, anti-Saccharomyces cerevisiae antibody, and NOD2/CARD15 genotype influence the progression of disease behavior in Crohn's disease.

Smith BR, Arnott ID, Drummond HE, Nimmo ER, Satsangi J. Smith BR, et al. Among authors: arnott id. Inflamm Bowel Dis. 2004 Sep;10(5):521-8. doi: 10.1097/00054725-200409000-00005. Inflamm Bowel Dis. 2004. PMID: 15472511

9

Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype.

Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. Arnott ID, et al. Am J Gastroenterol. 2004 Dec;99(12):2376-84. doi: 10.1111/j.1572-0241.2004.40417.x. Am J Gastroenterol. 2004. PMID: 15571586

10

Allelic variations of the multidrug resistance gene determine susceptibility and disease behavior in ulcerative colitis.

Ho GT, Nimmo ER, Tenesa A, Fennell J, Drummond H, Mowat C, Arnott ID, Satsangi J. Ho GT, et al. Among authors: arnott id. Gastroenterology. 2005 Feb;128(2):288-96. doi: 10.1053/j.gastro.2004.11.019. Gastroenterology. 2005. PMID: 15685540

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters